Abstract

Heme metabolism is central to malaria parasite biology. The parasite acquires heme from host hemoglobin in the intraerythrocytic stages and stores it as hemozoin to prevent free heme toxicity. The parasite can also synthesize heme de novo, and all the enzymes in the pathway are characterized. To study the role of the dual heme sources in malaria parasite growth and development, we knocked out the first enzyme, δ-aminolevulinate synthase (ALAS), and the last enzyme, ferrochelatase (FC), in the heme-biosynthetic pathway of Plasmodium berghei (Pb). The wild-type and knockout (KO) parasites had similar intraerythrocytic growth patterns in mice. We carried out in vitro radiolabeling of heme in Pb-infected mouse reticulocytes and Plasmodium falciparum-infected human RBCs using [4-14C] aminolevulinic acid (ALA). We found that the parasites incorporated both host hemoglobin-heme and parasite-synthesized heme into hemozoin and mitochondrial cytochromes. The similar fates of the two heme sources suggest that they may serve as backup mechanisms to provide heme in the intraerythrocytic stages. Nevertheless, the de novo pathway is absolutely essential for parasite development in the mosquito and liver stages. PbKO parasites formed drastically reduced oocysts and did not form sporozoites in the salivary glands. Oocyst production in PbALASKO parasites recovered when mosquitoes received an ALA supplement. PbALASKO sporozoites could infect mice only when the mice received an ALA supplement. Our results indicate the potential for new therapeutic interventions targeting the heme-biosynthetic pathway in the parasite during the mosquito and liver stages.

Highlights

  • Plasmodium falciparum (Pf) and Plasmodium vivax account for more than 95% of human malaria

  • We demonstrated about two decades ago that the malaria parasite could make heme on its own, it imports heme from red blood cell hemoglobin during the blood stages of infection

  • We investigated the role of parasitesynthesized heme in all stages of parasite growth by knocking out two genes in the heme-biosynthetic pathway of Plasmodium berghei that infects mice

Read more

Summary

Introduction

Plasmodium falciparum (Pf) and Plasmodium vivax account for more than 95% of human malaria. P. falciparum is widely resistant to the antimalarial drugs chloroquine (CQ) and antifolates. Emerging resistance to the artemisinin-based combination therapies [2] and the absence of an effective vaccine highlight an urgent need to develop new drug targets and vaccine candidates [3], [4]. The de novo hemebiosynthetic pathway of the malaria parasite offers potential drug targets and new vaccine candidates. The malaria parasite is capable of de novo heme biosynthesis despite its ability to acquire heme from red blood cell (RBC) hemoglobin. The parasite detoxifies hemoglobin-heme by converting it into hemozoin [5], [6]. The role of the de novo heme-biosynthetic pathway throughout the entire parasite life cycle is a subject of considerable interest [7]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call